Clinical Trials on Cancer Malignancies in United Kingdom
Total 24572 results
-
MEI Pharma, Inc.Quotient ClinicalCompleted
-
AstraZenecaQuintiles, Inc.CompletedSolid MalignanciesUnited Kingdom
-
Kiromic, Inc.TerminatedCancer | Progressive Solid Malignancies | Refractory Solid MalignanciesUnited States
-
Nottingham University Hospitals NHS TrustNewcastle University; University of Kansas; Macmillan Cancer Support; Bishop Grosseteste...TerminatedCancer | Oncologic Disorders | Nutrition Aspect of Cancer | Haematological MalignancyUnited Kingdom
-
AstraZenecaCompletedAdvanced Solid MalignanciesUnited Kingdom
-
PfizerCompletedAdvanced Non-Hematologic MalignanciesUnited Kingdom
-
Royal Cornwall Hospitals TrustCompletedPalliative Care | Hematologic Malignancy | Oncology | End Stage CancerUnited Kingdom
-
AstraZenecaTerminatedCancer | Advanced Solid MalignanciesUnited States, Italy, United Kingdom, France, Germany, Spain, Netherlands
-
Sumitomo Pharma America, Inc.CompletedCancer, Advanced MalignanciesCanada, United States
-
AstraZenecaParexelCompletedAdvanced MalignanciesUnited Kingdom, United States
-
Eisai Inc.CompletedSolid Tumor Malignancies, CancerUnited States
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United KingdomUnknownAdvanced Solid MalignanciesUnited Kingdom
-
Human Genome Sciences Inc.TerminatedLymphoid MalignanciesUnited States, United Kingdom
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Nonhematologic MalignanciesUnited States, Spain, United Kingdom
-
PfizerTerminatedAdvanced Non-Hematologic MalignanciesUnited States, United Kingdom
-
MedImmune LLCCompletedCancer | B-cell MalignanciesUnited States, Italy, Belgium, Canada, Spain
-
AstraZenecaTerminatedSolid Tumors | Advanced Solid Malignancies | Cancer,United States
-
Boston PharmaceuticalsCompletedAdvanced Nonhaematologic MalignanciesUnited Kingdom
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
BioInvent International ABMerck Sharp & Dohme LLCRecruitingAdvanced MalignanciesUnited Kingdom, Denmark, Hungary, Russian Federation
-
PCI Biotech ASCompletedCutaneous or Sub-cutaneous MalignanciesUnited Kingdom
-
Gilead SciencesCompletedRelapsed/Refractory B-cell MalignanciesFrance, United Kingdom
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
University College, LondonCompletedCD19+ Malignancies: Relapse Post-allogeneic TransplantUnited Kingdom
-
Gilead SciencesActive, not recruitingB-cell MalignanciesUnited States, United Kingdom, France
-
Nottingham University Hospitals NHS TrustUniversity of Nottingham; University of Sheffield; Sheffield Teaching Hospitals...CompletedNutrition Aspect of Cancer | Stem Cell Transplant Complications | Prehabilitation | Haematological Malignancy | Nutritional and Metabolic Disease | Bone Marrow Transplant Complications | Exercise InterventionsUnited Kingdom
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI)CompletedCancer MalignanciesUnited States
-
Incyte CorporationTerminatedMetastatic Cancer | Solid Tumors | Advanced MalignanciesUnited States, United Kingdom, Spain
-
Janssen Research & Development, LLCActive, not recruitingAdvanced Solid MalignanciesUnited States, United Kingdom, Canada, Korea, Republic of
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Nonhematologic MalignanciesUnited States, Spain, France, United Kingdom
-
Novartis PharmaceuticalsRecruitingContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesSpain, Taiwan, United States, Singapore, France
-
Carrick Therapeutics LimitedCompletedAdvanced Solid MalignanciesUnited States, United Kingdom
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplant | Haematological Malignancies | CD56+CD3- NK CellsUnited Kingdom
-
Gilead SciencesCompletedMyeloid MalignanciesUnited States, Australia, United Kingdom
-
University College, LondonMedical Research CouncilCompletedHaematological MalignanciesUnited Kingdom
-
CelgeneActive, not recruitingNeoplasms | Hematologic Malignancies | Hematologic NeoplasmUnited Kingdom, United States
-
AstraZenecaActive, not recruitingPediatric Cancer | Hematological Malignancies | Solid Tumor PediatricSpain, Italy, United States, United Kingdom, France, Netherlands, Germany
-
BeiGeneCompletedB-cell MalignanciesUnited States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
-
Regeneron PharmaceuticalsSanofiCompletedAdvanced Cancer | Advanced MalignanciesUnited States, Spain, Australia
-
AstraZenecaParexelActive, not recruitingAdvanced Haematological MalignanciesSpain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
-
Novartis PharmaceuticalsCompletedCancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological MalignanciesUnited States
-
Incyte CorporationTerminatedMetastatic Cancer | Solid Tumors | Advanced MalignanciesUnited States
-
The Christie NHS Foundation TrustRecruitingCOVID | Oncology | Haematological MalignancyUnited Kingdom
-
Kiromic, Inc.WithdrawnCancer | Hematologic MalignanciesUnited States
-
Cristina GasparettoAgilent Technologies, Inc.Active, not recruitingLymphoid Malignancies | Myeloid MalignanciesUnited States
-
Kah Poh LohWithdrawn
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Active, not recruitingHematopoietic/Lymphoid Cancer | Hematologic Malignancy | Blood CancerUnited States
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM)CompletedHematopoietic/Lymphoid Cancer | Hematologic Malignancy | Blood CancerUnited States
-
Regeneron PharmaceuticalsSanofiCompletedMalignanciesUnited States, Korea, Republic of, Australia, Ireland, United Kingdom
-
Dartmouth-Hitchcock Medical CenterRecruitingCancer | Hematologic Malignancy | Blood Cancer | Tumor, SolidUnited States